CONCLUDE was a randomised, open-label, treat-to-target, multinational trial comparing the risk of hypoglycaemia with Tresiba vs insulin glargine U300 in 1,609 adults with type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback